In a nutshell Tirzepatide (Mounjaro) produced 20.2% weight loss compared to semaglutide’s (Wegovy) 13.7% after 72 weeks of ...

Eli Lilly's tirzepatide showed significantly greater weight loss than Novo Nordisk's semaglutide in a 72-week clinical trial ...

Both medications were prescribed as weekly injections for patients clinically classified as obese, and were recommended ...

Mounjaro, manufactured by US drugmaker, and Wegovy by Danish drugmaker Novo Nordisk, cause weight loss by suppressing the ...

Eli Lilly and Company announced on Monday detailed results from SURMOUNT-5, a phase 3b open-label clinical trial, evaluating ...

The first head-to-head trial of Mounjaro and Wegovy, the weight-loss drugs, compared the effectiveness of the two leading ...

Both Mounjaro (tirzepatide) and Wegovy (semaglutide) are weight-loss medicines that make people feel fuller for longer and ...

WGN’s Dina Bair has the latest on new medical information, including: Study: Mounjaro helped people achieve more weight loss ...

Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.

GLP-1 drug Zepbound leads to greater weight and waist loss than Wegovy in 72-week trial, say researchers at European Congress ...

The ingredient tirzepatide, available as Mounjaro, has long been hailed the 'King Kong' of slimming jabs and a breakthrough in the war on obesity. Now, US researchers have found those on the ...